An overview of antibody-drug conjugates in oncological practice

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a precision medicine approach, combining antibody-based targeting with potent chemotherapy.
• ADCs aim to improve the therapeutic index by selectively delivering cytotoxic agents to cancer cells, minimizing systemic toxicity.
• Advancements in ADC technology and clinical experience are accelerating their development and application in various cancers.

Purpose of the Study:

• To provide an updated overview of ADCs approved by the US Food and Drug Administration (FDA).
• To examine the clinical evolution and pivotal trials of these approved ADCs.
• To review ongoing late-stage studies and emerging ADC candidates in oncology.

Main Methods:

• Review of FDA-approved ADCs and their indications.
• Analysis of clinical trial data supporting ADC approvals.
• Survey of current research on ADCs in non-approved settings and new candidates.

Main Results:

• Eight ADCs have been approved by the FDA for oncological practice.
• Significant clinical development has occurred, with four new ADCs approved recently.
• Ongoing studies are exploring expanded indications and new ADC therapies.

Conclusions:

• ADCs are a rapidly advancing therapeutic modality in oncology.
• The clinical utility of ADCs is expected to grow with further research and data.
• ADCs are poised to significantly reshape future cancer treatment strategies.